The PAC-MANN test was able to differentiate — 98% of the time — between the blood of someone with pancreatic cancer and the blood of someone who doesn’t have the disease. When used alongside the ...

Scientists have long struggled to target proteins that lack defined structure and are involved in cancer, neurodegenerative disorders like Parkinson's disease, and other serious illnesses. Now, a new ...

Liu Cuihua's group at the Institute of Microbiology of the Chinese Academy of Sciences revealed a pathogenic mechanism by which Mtb manipulates host lysosomal protease activity-dependent ...

The new blood-based assay PAC-MANN-1 (protease activity–based cancer marker using magnetic nanosensor-1) identified pancreatic ductal adenocarcinoma (PDAC) across all stages with high ...

The study demonstrates that PAC-MANN-1 outperforms the widely used CA 19-9 biomarker, offering greater accuracy in detecting all stages of PDAC. The assay is particularly promising for identifying ...

Pathogens can produce analogous proteases to subvert the host immune response. The balance in activity between a protease and its inhibitor can tune the immune response or cause damage as a result ...

We speculated that the low catalytic activity of the native p6 pol-protease precursor that is observed preceding its maturation may be an intrinsic feature of the dimeric precursor. Alternatively ...

In recent study, PAC-MANN identified pancreatic ductal adenocarcinoma samples with 98 percent specificity and 73 percent sensitivity across all stages.

and its second immunoglobulin protease pipeline candidate engineered to have potent enzymatic activity with optimized therapeutic properties. The in vitro and in vivo data supporting S‑8484 are ...

“Production of proteases is a hallmark of cancer progression and circulating protease activity may inform diagnosis of certain cancers,” researchers wrote in the journal, Science Translational ...